Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Amgen initiated with an Equal Weight at Wells Fargo » 16:31
12/08/21
12/08
16:31
12/08/21
16:31
AMGN

Amgen

$213.54 /

+2.24 (+1.06%)

Wells Fargo analyst Mohit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$213.54 /

+2.24 (+1.06%)

AMGN Amgen
$213.54 /

+2.24 (+1.06%)

12/06/21 Goldman Sachs
Amgen initiated with a Buy at Goldman Sachs
11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
AMGN Amgen
$213.54 /

+2.24 (+1.06%)

AMGN Amgen
$213.54 /

+2.24 (+1.06%)

AMGN Amgen
$213.54 /

+2.24 (+1.06%)

Monday
Hot Stocks
Amgen announces new data to be presented at ASH 2021 » 16:12
12/06/21
12/06
16:12
12/06/21
16:12
AMGN

Amgen

$208.76 /

+6.34 (+3.13%)

Amgen announced new data…

Amgen announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society of Hematology Annual Meeting & Exposition in Atlanta, Georgia, and virtually, from Dec. 11-14, 2021. Amgen will present data on its bispecific T-cell engager platform, including BLINCYTO, as well as KYPROLIS and Nplate. Updated data from the Phase 3 '215 trial in children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia showed BLINCYTO improved event-free survival and overall survival versus chemotherapy before allogeneic hematopoietic stem cell transplant. The first presentation of safety and efficacy data with BLINCYTO administered subcutaneously in adults with relapsed or refractory B-ALL also demonstrated encouraging results. Additionally, results from the Phase 1b study investigating KYPROLIS in combination with vincristine, dexamethasone, PEG-asparaginase, daunorubicin induction therapy in children with relapsed or refractory ALL showing promising efficacy in highly advanced relapsed/refractory pediatric ALL will be presented in a poster discussion session. Analyses from the Pregnancy Surveillance Program evaluating pregnancy and fetal outcomes of women exposed to Nplate highlighting no substantial safety concerns identified for mothers, fetuses and infants due to Nplate use during pregnancy will also be shared as an oral presentation on Monday, Dec. 13, 2021.

ShowHide Related Items >><<
AMGN Amgen
$208.76 /

+6.34 (+3.13%)

AMGN Amgen
$208.76 /

+6.34 (+3.13%)

12/06/21 Goldman Sachs
Amgen initiated with a Buy at Goldman Sachs
11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
AMGN Amgen
$208.76 /

+6.34 (+3.13%)

AMGN Amgen
$208.76 /

+6.34 (+3.13%)

AMGN Amgen
$208.76 /

+6.34 (+3.13%)

Initiation
Amgen initiated with a Buy at Goldman Sachs » 06:16
12/06/21
12/06
06:16
12/06/21
06:16
AMGN

Amgen

$202.42 /

+1.3 (+0.65%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter initiated coverage of Amgen with a Buy rating and $258 price target. The company has a diversified global portfolio of commercial innovator products and biosimilars, Richter tells investors in a research note. The analyst optimistic that Amgen's new product cycles can mostly offset the end-of-decade loss of exclusivity. Further, its early pipeline and business development serve as sources of growth, says Richter.

ShowHide Related Items >><<
AMGN Amgen
$202.42 /

+1.3 (+0.65%)

AMGN Amgen
$202.42 /

+1.3 (+0.65%)

11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
AMGN Amgen
$202.42 /

+1.3 (+0.65%)

AMGN Amgen
$202.42 /

+1.3 (+0.65%)

AMGN Amgen
$202.42 /

+1.3 (+0.65%)

Friday
Hot Stocks
Amgen raises quarterly dividend 10% to $1.94 per share » 16:00
12/03/21
12/03
16:00
12/03/21
16:00
AMGN

Amgen

$201.76 /

+0.64 (+0.32%)

Amgen announced that its…

Amgen announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022, to all stockholders of record as of the close of business on February 15, 2022. This represents a 10% increase from that paid in each of the previous four quarters.

ShowHide Related Items >><<
AMGN Amgen
$201.76 /

+0.64 (+0.32%)

AMGN Amgen
$201.76 /

+0.64 (+0.32%)

11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
AMGN Amgen
$201.76 /

+0.64 (+0.32%)

AMGN Amgen
$201.76 /

+0.64 (+0.32%)

AMGN Amgen
$201.76 /

+0.64 (+0.32%)

Over a week ago
Hot Stocks
AbCellera appoints Neil Aubuchon as chief commercial officer » 09:03
12/02/21
12/02
09:03
12/02/21
09:03
ABCL

AbCellera

$14.61 /

-0.4 (-2.66%)

, AMGN

Amgen

$200.66 /

+1.78 (+0.90%)

AbCellera (ABCL)…

AbCellera (ABCL) announced the appointment of Neil Aubuchon as chief commercial officer, or CCO. Aubuchon brings over 20 years of experience in strategic planning, operations, and leadership for global biopharmaceutical companies. As chief commercial officer, Aubuchon will lead the commercial strategy and assessment of partnership opportunities to optimize the value of AbCellera's growing portfolio of royalty positions in the next generation of antibody-based therapies. Prior to joining AbCellera, Aubuchon was the global marketing lead for Amgen's (AMGN) general medicine early portfolio.

ShowHide Related Items >><<
AMGN Amgen
$200.66 /

+1.78 (+0.90%)

ABCL AbCellera
$14.61 /

-0.4 (-2.66%)

ABCL AbCellera
$14.61 /

-0.4 (-2.66%)

11/18/21 Piper Sandler
AbCellera initiated with an Overweight at Piper Sandler
11/05/21 Stifel
Stifel sees 'zero change' to Adagio, AbCellera theses due to Pfizer data
10/01/21 Stifel
AbCellera, Adagio reactions to Merck data look 'overdone,' says Stifel
06/11/21 BMO Capital
AbCellera coverage transferred at BMO Capital
AMGN Amgen
$200.66 /

+1.78 (+0.90%)

11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
AMGN Amgen
$200.66 /

+1.78 (+0.90%)

ABCL AbCellera
$14.61 /

-0.4 (-2.66%)

  • 11
    Dec
AMGN Amgen
$200.66 /

+1.78 (+0.90%)

ABCL AbCellera
$14.61 /

-0.4 (-2.66%)

AMGN Amgen
$200.66 /

+1.78 (+0.90%)

ABCL AbCellera
$14.61 /

-0.4 (-2.66%)

On The Fly
Wall Street in Fives - Must Read Lists for Wednesday » 16:28
12/01/21
12/01
16:28
12/01/21
16:28
CRM

Salesforce

$251.50 /

-33.51 (-11.76%)

, XOM

Exxon Mobil

$59.78 /

-0.02 (-0.03%)

, HPE

HP Enterprise

$14.20 /

-0.18 (-1.25%)

, MRK

Merck

$74.43 /

-0.43 (-0.57%)

, SPX

S&P 500

/

+

, SPY

SPDR S&P 500 ETF Trust

$450.52 /

-5.32 (-1.17%)

, DNUT

Krispy Kreme

$13.18 /

-1.33 (-9.17%)

, DASH

DoorDash

$161.43 /

-17.335 (-9.70%)

, COF

Capital One

$138.35 /

-2.145 (-1.53%)

, DHI

D.R. Horton

$97.76 /

+0.02 (+0.02%)

, LEN

Lennar

$108.58 /

+3.52 (+3.35%)

, SKX

Skechers

$44.56 /

-0.36 (-0.80%)

, MRNA

Moderna

$310.58 /

-42.12 (-11.94%)

, AZN

AstraZeneca

$54.88 /

+0.05 (+0.09%)

, ABUS

Arbutus Biopharma

$4.60 /

+1.4 (+43.75%)

, JNJ

Johnson & Johnson

$158.16 /

+2.2 (+1.41%)

, AMGN

Amgen

$200.66 /

+1.78 (+0.90%)

, BBW

Build-A-Bear

$21.56 /

+4.67 (+27.65%)

, GIII

G-III Apparel

$30.47 /

+0.73 (+2.45%)

, BYSI

BeyondSpring

$4.94 /

-7.825 (-61.32%)

, CTIC

CTI BioPharma

$1.62 /

-0.615 (-27.52%)

, BIRD

Allbirds

$16.04 /

-3.235 (-16.78%)

, BOX

Box

$25.84 /

+2.37 (+10.10%)

, GFS

GlobalFoundries

$66.10 /

-3.32 (-4.78%)

, AMBA

Ambarella

$204.60 /

+24.69 (+13.72%)

, ZS

Zscaler

$318.19 /

-29.02 (-8.36%)

, GCP

GCP Applied Technologies

$26.65 /

+3.295 (+14.11%)

, BALY

Bally's

$35.65 /

-2.7 (-7.04%)

, WYNN

Wynn Resorts

$76.11 /

-5.01 (-6.18%)

, CZR

Caesars

$83.16 /

-6.855 (-7.62%)

Get caught up quickly on…

ShowHide Related Items >><<
ZS Zscaler
$318.19 /

-29.02 (-8.36%)

XOM Exxon Mobil
$59.78 /

-0.02 (-0.03%)

WYNN Wynn Resorts
$76.11 /

-5.01 (-6.18%)

SPY SPDR S&P 500 ETF Trust
$450.52 /

-5.32 (-1.17%)

SPX S&P 500
/

+

SKX Skechers
$44.56 /

-0.36 (-0.80%)

MRNA Moderna
$310.58 /

-42.12 (-11.94%)

MRK Merck
$74.43 /

-0.43 (-0.57%)

LEN Lennar
$108.58 /

+3.52 (+3.35%)

JNJ Johnson & Johnson
$158.16 /

+2.2 (+1.41%)

HPE HP Enterprise
$14.20 /

-0.18 (-1.25%)

GIII G-III Apparel
$30.47 /

+0.73 (+2.45%)

GFS GlobalFoundries
$66.10 /

-3.32 (-4.78%)

GCP GCP Applied Technologies
$26.65 /

+3.295 (+14.11%)

DNUT Krispy Kreme
$13.18 /

-1.33 (-9.17%)

DHI D.R. Horton
$97.76 /

+0.02 (+0.02%)

DASH DoorDash
$161.43 /

-17.335 (-9.70%)

CZR Caesars
$83.16 /

-6.855 (-7.62%)

CTIC CTI BioPharma
$1.62 /

-0.615 (-27.52%)

CRM Salesforce
$251.50 /

-33.51 (-11.76%)

COF Capital One
$138.35 /

-2.145 (-1.53%)

BYSI BeyondSpring
$4.94 /

-7.825 (-61.32%)

BOX Box
$25.84 /

+2.37 (+10.10%)

BBW Build-A-Bear
$21.56 /

+4.67 (+27.65%)

BALY Bally's
$35.65 /

-2.7 (-7.04%)

AZN AstraZeneca
$54.88 /

+0.05 (+0.09%)

AMGN Amgen
$200.66 /

+1.78 (+0.90%)

AMBA Ambarella
$204.60 /

+24.69 (+13.72%)

ABUS Arbutus Biopharma
$4.60 /

+1.4 (+43.75%)

CRM Salesforce
$251.50 /

-33.51 (-11.76%)

12/01/21 Jefferies
Salesforce promotion of Taylor to co-CEO a positive, says Jefferies
12/01/21 Morgan Stanley
Salesforce Q3 'likely fell short' of expectations, says Morgan Stanley
12/01/21 Truist
Salesforce price target raised to $330 from $315 at Truist
12/01/21 UBS
Salesforce price target lowered to $315 from $330 at UBS
XOM Exxon Mobil
$59.78 /

-0.02 (-0.03%)

11/02/21
Fly Intel: Top five analyst downgrades
11/02/21 Truist
Exxon Mobil downgraded to Sell from Hold at Truist
11/02/21 Truist
Exxon Mobil downgraded to Sell from Hold at Truist
10/21/21 Morgan Stanley
Exxon Mobil, Chevron look poised for 'catch up trade,' says Morgan Stanley
HPE HP Enterprise
$14.20 /

-0.18 (-1.25%)

12/01/21 Raymond James
HP Enterprise price target raised to $21 from $20 at Raymond James
12/01/21 Citi
Citi cuts HP Enterprise target, opens pair trade with NetApp
11/11/21 Goldman Sachs
HP Enterprise downgraded to Sell from Neutral at Goldman Sachs
10/06/21 Morgan Stanley
HP Enterprise price target lowered to $16 from $18 at Morgan Stanley
MRK Merck
$74.43 /

-0.43 (-0.57%)

11/29/21
Fly Intel: Top five analyst downgrades
11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 Citi
Merck downgraded to Neutral from Buy at Citi
SPX S&P 500
/

+

11/26/21 Morgan Stanley
Covid variant mutations may reduce vaccine effectiveness, says Morgan Stanley
11/26/21 Credit Suisse
Concerns over new Covid variant 'understandable,' says Credit Suisse
11/22/21 BTIG
In picking Powell, Biden went with 'safest choice,' says BTIG
08/04/21 Citi
Citi sees 10-year yield rising to 2%, cuts 'tech-heavy' U.S. to Neutral
SPY SPDR S&P 500 ETF Trust
$450.52 /

-5.32 (-1.17%)

DNUT Krispy Kreme
$13.18 /

-1.33 (-9.17%)

12/01/21
Fly Intel: Top five analyst downgrades
12/01/21 Goldman Sachs
Krispy Kreme downgraded to Sell from Neutral at Goldman Sachs
11/08/21
Fly Intel: Top five analyst downgrades
11/08/21 Truist
Krispy Kreme downgraded to Hold from Buy at Truist
DASH DoorDash
$161.43 /

-17.335 (-9.70%)

12/02/21 UBS
DoorDash initiated with a Neutral at UBS
12/01/21
Fly Intel: Top five analyst upgrades
12/01/21 Gordon Haskett
Gordon Haskett sees 'compelling re-entry point,' upgrades DoorDash to Buy
12/01/21 Gordon Haskett
DoorDash upgraded to Buy from Hold at Gordon Haskett
COF Capital One
$138.35 /

-2.145 (-1.53%)

12/01/21 Baird
Capital One upgraded to Neutral after underperformance at Baird
12/01/21 Baird
Capital One upgraded to Neutral from Underperform at Baird
10/27/21 Credit Suisse
Capital One price target raised to $190 from $184 at Credit Suisse
DHI D.R. Horton
$97.76 /

+0.02 (+0.02%)

12/01/21 Goldman Sachs
D.R. Horton downgraded to Neutral from Buy at Goldman Sachs
11/17/21 Raymond James
D.R. Horton price target raised to $120 from $110 at Raymond James
11/11/21 Citi
D.R. Horton price target raised to $116 from $104 at Citi
LEN Lennar
$108.58 /

+3.52 (+3.35%)

12/01/21 Goldman Sachs
Lennar upgraded to Buy from Neutral at Goldman Sachs
11/08/21 BofA
Lennar reinstated with a Buy at BofA
10/14/21 JPMorgan
Lennar price target lowered to $127 from $143 at JPMorgan
SKX Skechers
$44.56 /

-0.36 (-0.80%)

11/02/21 Argus
Skechers downgraded to Hold from Buy at Argus
10/29/21 B. Riley
Skechers growth thesis intact despite Q3 miss, says B. Riley
10/19/21
Fly Intel: Top five analyst upgrades
MRNA Moderna
$310.58 /

-42.12 (-11.94%)

11/28/21 Piper Sandler
Moderna has multiple booster candidates to combat omicron, says Piper Sandler
11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
AZN AstraZeneca
$54.88 /

+0.05 (+0.09%)

11/29/21 Morgan Stanley
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Morgan Stanley
11/22/21 Bryan Garnier
AstraZeneca downgraded to Buy from Conviction Buy at Bryan Garnier
10/27/21 SVB Leerink
Seagen price target raised to $200 from $190 at SVB Leerink
10/19/21 UBS
AstraZeneca price target raised to 10,000 GBp from 9,200 GBp at UBS
ABUS Arbutus Biopharma
$4.60 /

+1.4 (+43.75%)

12/02/21 Chardan
Arbutus Biopharma price target raised to $5.50 from $5 at Chardan
11/08/21 H.C. Wainwright
Arbutus Biopharma price target lowered to $8 from $10 at H.C. Wainwright
06/28/21 JMP Securities
Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
03/10/21 B. Riley
Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
JNJ Johnson & Johnson
$158.16 /

+2.2 (+1.41%)

11/29/21 Credit Suisse
Credit Suisse stays Outperform on J&J as intra-quarter checks find pharma upside
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
AMGN Amgen
$200.66 /

+1.78 (+0.90%)

11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
BBW Build-A-Bear
$21.56 /

+4.67 (+27.65%)

GIII G-III Apparel
$30.47 /

+0.73 (+2.45%)

06/08/21 B. Riley
G-III Apparel price target raised to $41 from $39 at B. Riley
06/08/21 Barclays
G-III Apparel price target raised to $30 from $27 at Barclays
03/19/21 B. Riley
G-III Apparel price target raised to $38 from $33 at B. Riley Securities
03/19/21 Barclays
G-III Apparel price target raised to $27 from $24 at Barclays
BYSI BeyondSpring
$4.94 /

-7.825 (-61.32%)

12/02/21 Jefferies
Jefferies cuts BeyondSpring to Hold, slashes target to $5 after plinabulin CRL
12/02/21 Jefferies
BeyondSpring downgraded to Hold from Buy at Jefferies
12/01/21 BofA
BeyondSpring downgraded to Underperform from Buy at BofA
12/01/21 William Blair
BeyondSpring cut to Market Perform at William Blair after CRL for plinabulin
CTIC CTI BioPharma
$1.62 /

-0.615 (-27.52%)

12/01/21 Lake Street
CTI BioPharma delay creates buying opportunity, says Lake Street
10/04/21 Lake Street
CTI BioPharma should be bought on weakness after PRE-VENT miss, says Lake Street
08/09/21 BTIG
CTI BioPharma initiated with a Buy at BTIG
06/01/21 Lake Street
CTI BioPharma price target raised to $15 from $13 at Lake Street
BIRD Allbirds
$16.04 /

-3.235 (-16.78%)

12/01/21 Morgan Stanley
Morgan Stanley says Allbirds investors may have been seeking upside
11/29/21
Fly Intel: Top five analyst initiations
11/29/21 Guggenheim
Guggenheim starts Allbirds at Buy, sees 50% potential upside
11/29/21 Guggenheim
Allbirds initiated with a Buy at Guggenheim
BOX Box
$25.84 /

+2.37 (+10.10%)

12/02/21 Berenberg
Box price target raised to $34 from $30 at Berenberg
12/01/21 Craig-Hallum
Box price target raised to $38 from $31 at Craig-Hallum
12/01/21 Morgan Stanley
Box price target raised to $30 at Morgan Stanley after 'beat and raise quarter'
12/01/21 Raymond James
Box price target raised to $30 from $29 at Raymond James
GFS GlobalFoundries
$66.10 /

-3.32 (-4.78%)

12/01/21 Morgan Stanley
GlobalFoundries target up to $68 at Morgan Stanley after 'solid' first report
12/01/21 Credit Suisse
GlobalFoundries price target raised to $80 from $75 at Credit Suisse
12/01/21 Deutsche Bank
GlobalFoundries price target raised to $78 from $75 at Deutsche Bank
11/22/21
Fly Intel: Top five analyst initiations
AMBA Ambarella
$204.60 /

+24.69 (+13.72%)

12/01/21 Colliers
Ambarella price target raised to $245 from $135 at Colliers
12/01/21 Cowen
Ambarella price target raised to $235 from $150
12/01/21 Craig-Hallum
Ambarella price target raised to $250 from $170 at Craig-Hallum
12/01/21 Morgan Stanley
Ambarella price target raised to $229 from $222 at Morgan Stanley
ZS Zscaler
$318.19 /

-29.02 (-8.36%)

12/01/21 Truist
Zscaler price target raised to $400 from $325 at Truist
12/01/21 Wedbush
Zscaler price target raised to $400 from $320 at Wedbush
12/01/21 Canaccord
Zscaler price target raised to $400 from $340 at Canaccord
12/01/21 Needham
Zscaler price target raised to $418 from $390 at Needham
GCP GCP Applied Technologies
$26.65 /

+3.295 (+14.11%)

BALY Bally's
$35.65 /

-2.7 (-7.04%)

11/09/21 KeyBanc
Bally's price target lowered to $65 from $70 at KeyBanc
10/27/21
Fly Intel: Top five analyst initiations
10/27/21 Goldman Sachs
Bally's initiated with a Neutral at Goldman Sachs
10/26/21
Fly Intel: Top five analyst upgrades
WYNN Wynn Resorts
$76.11 /

-5.01 (-6.18%)

11/10/21 Wells Fargo
Wynn Resorts price target lowered to $101 from $112 at Wells Fargo
11/10/21 Deutsche Bank
Wynn Resorts price target lowered to $131 from $140 at Deutsche Bank
11/10/21 Stifel
Wynn Resorts price target raised to $124 from $107 at Stifel
10/20/21 Morgan Stanley
Wynn Resorts price target lowered to $107 from $113 at Morgan Stanley
CZR Caesars
$83.16 /

-6.855 (-7.62%)

11/29/21 Deutsche Bank
Caesars price target lowered to $130 from $132 at Deutsche Bank
11/12/21
Fly Intel: Top five analyst initiations
11/12/21 B. Riley
B. Riley starts 'mispriced empire' Caesars with Buy, $191 target
11/12/21 B. Riley
Caesars initiated with a Buy at B. Riley
ZS Zscaler
$318.19 /

-29.02 (-8.36%)

XOM Exxon Mobil
$59.78 /

-0.02 (-0.03%)

WYNN Wynn Resorts
$76.11 /

-5.01 (-6.18%)

SKX Skechers
$44.56 /

-0.36 (-0.80%)

MRNA Moderna
$310.58 /

-42.12 (-11.94%)

MRK Merck
$74.43 /

-0.43 (-0.57%)

LEN Lennar
$108.58 /

+3.52 (+3.35%)

JNJ Johnson & Johnson
$158.16 /

+2.2 (+1.41%)

HPE HP Enterprise
$14.20 /

-0.18 (-1.25%)

GIII G-III Apparel
$30.47 /

+0.73 (+2.45%)

GFS GlobalFoundries
$66.10 /

-3.32 (-4.78%)

GCP GCP Applied Technologies
$26.65 /

+3.295 (+14.11%)

DNUT Krispy Kreme
$13.18 /

-1.33 (-9.17%)

DHI D.R. Horton
$97.76 /

+0.02 (+0.02%)

DASH DoorDash
$161.43 /

-17.335 (-9.70%)

CZR Caesars
$83.16 /

-6.855 (-7.62%)

CTIC CTI BioPharma
$1.62 /

-0.615 (-27.52%)

CRM Salesforce
$251.50 /

-33.51 (-11.76%)

COF Capital One
$138.35 /

-2.145 (-1.53%)

BYSI BeyondSpring
$4.94 /

-7.825 (-61.32%)

BOX Box
$25.84 /

+2.37 (+10.10%)

BIRD Allbirds
$16.04 /

-3.235 (-16.78%)

BBW Build-A-Bear
$21.56 /

+4.67 (+27.65%)

BALY Bally's
$35.65 /

-2.7 (-7.04%)

AZN AstraZeneca
$54.88 /

+0.05 (+0.09%)

AMGN Amgen
$200.66 /

+1.78 (+0.90%)

AMBA Ambarella
$204.60 /

+24.69 (+13.72%)

ABUS Arbutus Biopharma
$4.60 /

+1.4 (+43.75%)

  • 03
    Nov
  • 28
    Oct
  • 19
    Aug
  • 01
    Jul
  • 20
    May
  • 16
    Apr
  • 01
    Apr
  • 09
    Feb
  • 09
    Dec
ZS Zscaler
$318.19 /

-29.02 (-8.36%)

XOM Exxon Mobil
$59.78 /

-0.02 (-0.03%)

WYNN Wynn Resorts
$76.11 /

-5.01 (-6.18%)

SPX S&P 500
/

+

SKX Skechers
$44.56 /

-0.36 (-0.80%)

MRNA Moderna
$310.58 /

-42.12 (-11.94%)

MRK Merck
$74.43 /

-0.43 (-0.57%)

LEN Lennar
$108.58 /

+3.52 (+3.35%)

JNJ Johnson & Johnson
$158.16 /

+2.2 (+1.41%)

HPE HP Enterprise
$14.20 /

-0.18 (-1.25%)

GCP GCP Applied Technologies
$26.65 /

+3.295 (+14.11%)

DNUT Krispy Kreme
$13.18 /

-1.33 (-9.17%)

DHI D.R. Horton
$97.76 /

+0.02 (+0.02%)

DASH DoorDash
$161.43 /

-17.335 (-9.70%)

CRM Salesforce
$251.50 /

-33.51 (-11.76%)

COF Capital One
$138.35 /

-2.145 (-1.53%)

BOX Box
$25.84 /

+2.37 (+10.10%)

BALY Bally's
$35.65 /

-2.7 (-7.04%)

AZN AstraZeneca
$54.88 /

+0.05 (+0.09%)

ZS Zscaler
$318.19 /

-29.02 (-8.36%)

XOM Exxon Mobil
$59.78 /

-0.02 (-0.03%)

SPX S&P 500
/

+

SKX Skechers
$44.56 /

-0.36 (-0.80%)

MRNA Moderna
$310.58 /

-42.12 (-11.94%)

MRK Merck
$74.43 /

-0.43 (-0.57%)

LEN Lennar
$108.58 /

+3.52 (+3.35%)

JNJ Johnson & Johnson
$158.16 /

+2.2 (+1.41%)

HPE HP Enterprise
$14.20 /

-0.18 (-1.25%)

GIII G-III Apparel
$30.47 /

+0.73 (+2.45%)

GFS GlobalFoundries
$66.10 /

-3.32 (-4.78%)

DNUT Krispy Kreme
$13.18 /

-1.33 (-9.17%)

DHI D.R. Horton
$97.76 /

+0.02 (+0.02%)

DASH DoorDash
$161.43 /

-17.335 (-9.70%)

CRM Salesforce
$251.50 /

-33.51 (-11.76%)

COF Capital One
$138.35 /

-2.145 (-1.53%)

BYSI BeyondSpring
$4.94 /

-7.825 (-61.32%)

BOX Box
$25.84 /

+2.37 (+10.10%)

BALY Bally's
$35.65 /

-2.7 (-7.04%)

AZN AstraZeneca
$54.88 /

+0.05 (+0.09%)

AMGN Amgen
$200.66 /

+1.78 (+0.90%)

AMBA Ambarella
$204.60 /

+24.69 (+13.72%)

ABUS Arbutus Biopharma
$4.60 /

+1.4 (+43.75%)

ZS Zscaler
$318.19 /

-29.02 (-8.36%)

XOM Exxon Mobil
$59.78 /

-0.02 (-0.03%)

WYNN Wynn Resorts
$76.11 /

-5.01 (-6.18%)

SPY SPDR S&P 500 ETF Trust
$450.52 /

-5.32 (-1.17%)

SPX S&P 500
/

+

SKX Skechers
$44.56 /

-0.36 (-0.80%)

MRNA Moderna
$310.58 /

-42.12 (-11.94%)

MRK Merck
$74.43 /

-0.43 (-0.57%)

LEN Lennar
$108.58 /

+3.52 (+3.35%)

JNJ Johnson & Johnson
$158.16 /

+2.2 (+1.41%)

HPE HP Enterprise
$14.20 /

-0.18 (-1.25%)

GFS GlobalFoundries
$66.10 /

-3.32 (-4.78%)

DNUT Krispy Kreme
$13.18 /

-1.33 (-9.17%)

DHI D.R. Horton
$97.76 /

+0.02 (+0.02%)

DASH DoorDash
$161.43 /

-17.335 (-9.70%)

CZR Caesars
$83.16 /

-6.855 (-7.62%)

CRM Salesforce
$251.50 /

-33.51 (-11.76%)

COF Capital One
$138.35 /

-2.145 (-1.53%)

BYSI BeyondSpring
$4.94 /

-7.825 (-61.32%)

BOX Box
$25.84 /

+2.37 (+10.10%)

BIRD Allbirds
$16.04 /

-3.235 (-16.78%)

AZN AstraZeneca
$54.88 /

+0.05 (+0.09%)

AMGN Amgen
$200.66 /

+1.78 (+0.90%)

AMBA Ambarella
$204.60 /

+24.69 (+13.72%)

ABUS Arbutus Biopharma
$4.60 /

+1.4 (+43.75%)

SPY SPDR S&P 500 ETF Trust
$450.52 /

-5.32 (-1.17%)

SPX S&P 500
/

+

Hot Stocks
Amgen reports 'positive' results from Otezla Phase 3 DISCREET trial » 16:02
12/01/21
12/01
16:02
12/01/21
16:02
AMGN

Amgen

$201.47 /

+2.59 (+1.30%)

Amgen announced positive…

Amgen announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static Physician's Global Assessment of Genitalia response at week 16. In addition, all secondary endpoints were also met with meaningful and significant improvements in Genital Psoriasis Itch Numerical Rating Scale response; affected body surface area change from baseline; Dermatology Life Quality Index change from baseline; and static Physician's Global Assessment response at week 16 with Otezla versus placebo.

ShowHide Related Items >><<
AMGN Amgen
$201.47 /

+2.59 (+1.30%)

AMGN Amgen
$201.47 /

+2.59 (+1.30%)

11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
AMGN Amgen
$201.47 /

+2.59 (+1.30%)

AMGN Amgen
$201.47 /

+2.59 (+1.30%)

AMGN Amgen
$201.47 /

+2.59 (+1.30%)

Hot Stocks
Amgen announces FDA approves Kyprolis/Darzalex Faspro combo expansion » 13:32
12/01/21
12/01
13:32
12/01/21
13:32
AMGN

Amgen

$204.13 /

+5.25 (+2.64%)

, JNJ

Johnson & Johnson

$159.55 /

+3.59 (+2.30%)

Amgen (AMGN) announced…

Amgen (AMGN) announced that the U.S. Food and Drug Administration has approved the expansion of the Kyprolis U.S. prescribing information to include its use in combination with Darzalex Faspro and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. The expansion of the Kyprolis prescribing information to include Darzalex Faspro plus dexamethasone was supported by the ongoing, Phase 2, non-randomized, open-label, multicenter PLEIADES trial evaluating the clinical benefit of Darzalex Faspro administered in combination with four standard-of-care treatment regimens in patients with multiple myeloma. "I am pleased that the addition of subcutaneous daratumumab to Kyprolis plus dexamethasone will offer increased flexibility and convenience for patients with relapsed or refractory multiple myeloma and will greatly reduce the administration burden," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. Separately, the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) also announced the FDA approval of Darzalex Faspro in combination with Kyprolis and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy.

ShowHide Related Items >><<
JNJ Johnson & Johnson
$159.55 /

+3.59 (+2.30%)

AMGN Amgen
$204.13 /

+5.25 (+2.64%)

AMGN Amgen
$204.13 /

+5.25 (+2.64%)

11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
JNJ Johnson & Johnson
$159.55 /

+3.59 (+2.30%)

11/29/21 Credit Suisse
Credit Suisse stays Outperform on J&J as intra-quarter checks find pharma upside
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
JNJ Johnson & Johnson
$159.55 /

+3.59 (+2.30%)

AMGN Amgen
$204.13 /

+5.25 (+2.64%)

JNJ Johnson & Johnson
$159.55 /

+3.59 (+2.30%)

JNJ Johnson & Johnson
$159.55 /

+3.59 (+2.30%)

AMGN Amgen
$204.13 /

+5.25 (+2.64%)

JNJ Johnson & Johnson
$159.55 /

+3.59 (+2.30%)

AMGN Amgen
$204.13 /

+5.25 (+2.64%)

Hot Stocks
FDA approves J&J, Amgen treatments for multiple myeloma » 11:57
12/01/21
12/01
11:57
12/01/21
11:57
JNJ

Johnson & Johnson

$159.20 /

+3.24 (+2.08%)

, AMGN

Amgen

$204.55 /

+5.67 (+2.85%)

The Food and Drug…

The Food and Drug Administration announced the approval of Johnson & Johnson's (JNJ) daratumumab plus hyaluronidase-fihj and Amgen's (AMGN) carfilzomib plus dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. Reference Link

ShowHide Related Items >><<
JNJ Johnson & Johnson
$159.20 /

+3.24 (+2.08%)

AMGN Amgen
$204.55 /

+5.67 (+2.85%)

JNJ Johnson & Johnson
$159.20 /

+3.24 (+2.08%)

11/29/21 Credit Suisse
Credit Suisse stays Outperform on J&J as intra-quarter checks find pharma upside
11/09/21 Mizuho
Alkermes price target lowered to $33 from $36 at Mizuho
11/08/21 Morgan Stanley
Morgan Stanley bullish on 2seventy Bio, initiates with an Overweight
10/20/21 Raymond James
Johnson & Johnson price target lowered to $178 from $183 at Raymond James
AMGN Amgen
$204.55 /

+5.67 (+2.85%)

11/22/21 Mizuho
Amgen price target lowered to $194 from $222 at Mizuho
11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
JNJ Johnson & Johnson
$159.20 /

+3.24 (+2.08%)

AMGN Amgen
$204.55 /

+5.67 (+2.85%)

JNJ Johnson & Johnson
$159.20 /

+3.24 (+2.08%)

JNJ Johnson & Johnson
$159.20 /

+3.24 (+2.08%)

AMGN Amgen
$204.55 /

+5.67 (+2.85%)

JNJ Johnson & Johnson
$159.20 /

+3.24 (+2.08%)

AMGN Amgen
$204.55 /

+5.67 (+2.85%)

Recommendations
Amgen price target lowered to $194 from $222 at Mizuho » 06:52
11/22/21
11/22
06:52
11/22/21
06:52
AMGN

Amgen

$206.02 /

+1.96 (+0.96%)

Mizuho analyst Salim Syed…

Mizuho analyst Salim Syed lowered the firm's price target on Amgen to $194 from $222 and keeps a Neutral rating on the shares following the Q3 print. Into 2022, Amgen faces "several headwinds which are not being fully incorporated into consensus," Syed tells investors in a research note. His 2022 revenue estimate is $1B lower than the consensus of $27B.

ShowHide Related Items >><<
AMGN Amgen
$206.02 /

+1.96 (+0.96%)

AMGN Amgen
$206.02 /

+1.96 (+0.96%)

11/18/21 BMO Capital
Amgen initiated with a Market Perform at BMO Capital
11/01/21 Oppenheimer
Amgen price target lowered to $272 from $277 at Oppenheimer
10/04/21 Piper Sandler
Amgen's AMG 451 looks competitive with Dupixent, says Piper Sandler
09/23/21 Daiwa
Amgen downgraded to Neutral from Outperform at Daiwa
AMGN Amgen
$206.02 /

+1.96 (+0.96%)

AMGN Amgen
$206.02 /

+1.96 (+0.96%)

AMGN Amgen
$206.02 /

+1.96 (+0.96%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.